Asthma Management Handbook
Close window

Table. Australian Asthma Handbook Version 1.2 clinical amendments (additional amendments published March 2017)

Topic

Places(s) in text

Amendment

Rationale

Tiotropium

Managing severe, high-risk and difficult-to-control asthma in adults

Guide to other asthma medicines

Amendment of recommendation:

Tiotropium via mist inhaler can be considered as an add-on option in adults who have had a severe asthma flare-up within the previous year despite maintenance treatment with inhaled corticosteroid (equivalent to 800 microg budesonide/day or higher) in combination with a long-acting beta2agonist.

Amendment of More Information Topic Tiotropium for adults.

Clarification of add-on medicines for severe asthma and asthma-COPD overlap.

Amended to clarify indications for tiotropium (TGA approval in 2015).

Mepolizumab

Managing severe, high-risk and difficult-to-control asthma in adults

Managing allergies as part of asthma management

Amendment of recommendation and More Information Topic Mepolizumab to include criteria for PBS subsidy.

 

Amended to reflect PBS status for mepolizumab (PBS status updated January 2017).

Omalizumab

Conducting further review after adjustment of initial treatment in children 6 years and over

Managing allergies as part of asthma management

Amendment of recommendation and More Information Topic Omalizumab to include criteria for PBS subsidy.

Amended to reflect PBS status for omalizumab (PBS status updated January 2017).

Asset ID: 101